Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer
Authors:
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 40 (3) , 333-338
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Second-line chemotherapy and its evaluation in small cell lung cancerCancer Treatment Reviews, 1999
- Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.Journal of Clinical Oncology, 1998
- Establishment and Characterization of Acquired Resistance to Platinum Anticancer Drugs in Human Ovarian Carcinoma CellsJapanese Journal of Cancer Research, 1995
- Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancerAnnals of Oncology, 1994
- Effects of carboplatin in combination with other anticancer agents on human leukemia cell linesLeukemia Research, 1993
- CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.Journal of Clinical Oncology, 1992
- Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.Journal of Clinical Oncology, 1992
- Management of small-cell cancer of the lungThe Lancet, 1992
- Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IICancer Chemotherapy and Pharmacology, 1982